FDA grants fast-track status to Peregrine’s bavituximab for lung cancer treatment
The US Food and Drug Administration (FDA) has granted fast-track designation for Peregrine Pharmaceuticals’ lead investigational immunotherapy ‘bavituximab’ to treat patients with second-line non-small cell lung cancer (NSCLC).
Filed under: FAST TRACK FDA Tagged: Bavituximab, Fast Track Designation
